Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | HTR6 | P50406 | 19/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421968 | 0.80 | HTR6 (0.67) | HTR6HTR2C | |
| SCHEMBL1421915 | 0.80 | HTR6 (0.62) | HTR6HTR2CADRA2A | |
| SCHEMBL1423386 | 0.79 | HTR6 (0.58) | HTR6HTR2CADRA2A | |
| SCHEMBL1422178 | 0.77 | HTR6 (0.63) | HTR6HTR2C | |
| SCHEMBL1878504 | 0.77 | HTR6 (0.69) | HTR6HTR2CADRA2A | |
| SCHEMBL12659681 | 0.77 | HTR6 (0.55) | HTR6HTR2CADRA2A | |
| SCHEMBL1422650 | 0.77 | HTR6 (0.62) | HTR6HTR2C | |
| SCHEMBL1423661 | 0.77 | HTR6 (0.61) | HTR6HTR2CADRA2A | |
| SCHEMBL1423404 | 0.77 | HTR6 (0.60) | HTR6HTR2CADRA2A | |
| SCHEMBL1877628 | 0.77 | HTR6 (0.73) | HTR6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105555-A1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DE. DR. ESTEVE, S.A. (ES) | 2011-05-05 | — | — | US | claimed |
| US-20110105555-A1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DE. DR. ESTEVE, S.A. (ES) | 2011-05-05 | — | — | US | disclosed |
| US-20110105555-A1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DE. DR. ESTEVE, S.A. (ES) | 2011-05-05 | — | — | US | disclosed |
| EP-2116547-A1 | Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105555-A1 | SUBSTITUTED N-IMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | HTR6, HTR1A, HTR5A | KDM4E 4588/4885NPC1 1175/4885RAB9A 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.